NEW YORK, Sept. 23 (GenomeWeb News) - ParAllele BioScience said that it has raised $22.5 million in a round of Series B financing.
The round was led by a new investor, Mohr, Davidow Ventures, and included such existing investors as Abingworth Management, Index Ventures, and Versant Ventures.
Proceeds of the financing, said ParAllele, will be used to support the ongoing development and roll out of the company's SNP products.